The Syrian Consequence: Russia’s Withdrawal
By Peter Zeihan
Much has changed since I left for New Zealand a few days ago, and I’m sure everyone has already caught up on the Syrian unraveling. So, let’s dive into the history of Syria and the consequences that all this...
The federal government narrowly averted a year-end shutdown after an 11th-hour effort in the GOP-controlled House of Representatives to cobble a bill …
The Syrian Consequence: Russia’s Withdrawal
By Peter Zeihan
Much has changed since I left for New Zealand a few days ago, and I’m sure everyone has already...
BANGKOK (AP) — Japanese tycoon Masayoshi Son and President-elect Donald Trump have announced plans for technology and telecoms giant SoftBank Group to invest $100 billion in projects in the United States over the coming four years. Trump said the investments in building artificial intelligence …
The head of the ubiquitous chip design firm on the ‘breathtaking’ pace of AI. Earlier this month, I teased an upcoming interview with Rene Haas, CEO of chip design company Arm. I sat down live in Silicon Valley with Rene at an event hosted by AlixPartners, the full version of which is now …
The latest business trend? Donating $1 million to Donald Trump's inauguration. Business leaders across industries are trying to get on the president-elect's good side ahead of his return to the Oval Office, and some are breaking out their wallets — or their company's — to do so. The president-elect …
A handful of Silicon Valley executives could help transform the country’s largest bureaucracy — and benefit themselves while trying. A culture clash is headed for Washington that will pit the risk-embracing, fast-first nature of Silicon Valley against the lumbering bureaucracy of the country’s …
The weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by the U.S. Food and Drug Administration (FDA) to treat obstructive sleep apnea. In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists …
Shares of Danish pharmaceutical giant Novo Nordisk plummeted roughly 20% on Friday after reporting results in a late-stage trial for its experimental …